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Abstract
Connexin 43 (Cx43) mediates osteocyte communication with other cells and with the extracellular
milieu and regulates osteoblastic cell signaling and gene expression. We now report that mice
lacking Cx43 in osteoblasts/osteocytes or only in osteocytes (Cx43ΔOt mice) exhibit increased
osteocyte apoptosis, endocortical resorption and periosteal bone formation, resulting in higher
marrow cavity and total tissue areas measured at the femoral mid-diaphysis. Blockade of
resorption reversed the increased marrow cavity but not total tissue area, demonstrating that
endocortical resorption and periosteal apposition are independently regulated. Anatomical
mapping of apoptotic osteocytes, osteocytic protein expression, and resorption and formation,
suggests that Cx43 controls osteoclast and osteoblast activity by regulating osteoprotegerin and
sclerostin levels, respectively, in osteocytes located in specific areas of the cortex. Whereas empty
lacunae and living osteocytes lacking osteoprotegerin were distributed throughout cortical bone in
Cx43ΔOt mice, apoptotic osteocytes were preferentially located in areas containing osteoclasts,
suggesting that osteoclast recruitment requires active signaling from dying osteocytes.
Furthermore, Cx43 deletion in cultured osteocytic cells resulted in increased apoptosis and
decreased osteoprotegerin expression. Thus, Cx43 is essential in a cell-autonomous fashion in vivo
and in vitro for osteocyte survival and for controlling the expression of osteocytic genes that affect
osteoclast and osteoblast function.
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INTRODUCTION
Mounting evidence from recent years demonstrates that the concerted actions of bone
forming osteoblasts and bone resorbing osteoclasts, which are responsible for maintaining
the mass and geometry of the skeleton, are modulated by signals originating from
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osteocytes. Osteocytes are terminally differentiated osteoblasts that become entombed
during the process of bone deposition and reside embedded in the mineralized matrix, but
remain highly communicated among themselves and with other cellular elements on the
bone surface, the bone marrow, and the vasculature (1). Sclerostin, the product of the SOST
gene expressed in osteocytes, is one of the recognized molecular mediators by which
osteocytes modulate the function of the cells that remodel bone (2). Because sclerostin is a
potent inhibitor of bone formation, changes in its expression in human diseases or in
response to hormonal and mechanical stimuli, have a profound impact on bone mass.
Osteocytes also express proteins that modulate osteoclast formation and activity such as the
receptor activator of NF-κB (RANKL) and its decoy receptor osteoprotegerin (OPG) (3,4).
Moreover, overexpression of a constitutively active parathyroid hormone receptor 1 or
deletion of the Wnt canonical signaling mediator β-catenin in osteocytes, results in increased
RANKL/OPG ratio, osteoclast activity, and bone resorption (4-6). In addition, loss of
osteocyte viability induced by either too high or too low mechanical strains, by decreased
levels of sex hormones, or by genetically-induced osteocyte death, temporally precedes and
is spatially associated with osteoclast recruitment to the same location, a concept known as
targeted remodeling (7-11). However, it remains unknown whether osteoclastogenic
cytokines, other products derived from osteocytes, or apoptotic osteocytic bodies are
responsible for this phenomenon.
Channels formed by connexin 43 (Cx43), the most abundant member of the connexin family
of proteins expressed in bone cells, mediate the communication among osteocytes and
between osteocytes and cells on the bone surface (12). Gap junction channels established
between neighboring cells and hemichannels expressed in unopposed cell membranes allow
the passage of small size (<1 kDa) molecules among cells or between cells and their
extracellular milieu (13). Besides its participation in gap junctions and hemichannels, Cx43
might also affect osteoblast and osteocyte functions by interacting with structural and
signaling molecules, thereby modulating intracellular signaling and gene expression (14).
One of the best studied Cx43-interacting proteins is the kinase Src, an upstream regulator of
ERKs, which is required for the Cx43-dependent anti-apoptotic effect of bisphosphonates on
osteoblasts and osteocytes (15,16). Cx43 also interacts with β-arrestin, a modulator of G
protein-coupled receptors, and this association is indispensible for cAMP-mediated
responses downstream of the parathyroid receptor 1 in osteoblasts (17). Moreover, Cx43
modulates gene transcription in osteoblasts in vitro by altering transcription factor
recruitment to connexin response elements present in osteoblast-specific genes, such as
osteocalcin (18).
Several animal models have been developed to investigate the function of Cx43 in bone
forming cells in vivo and have demonstrated that lack of Cx43 expression is necessary at an
early stage during osteoblast differentiation. Thus, mice lacking Cx43 in
osteochondroprogenitors developed using the Dermo1 promoter to drive Cre
recombinase (19) or in early osteoblasts using the Col1-2.3kb promoter (20) have delayed
mineralization and low bone mass, due to decreased osteoblast differentiation and function.
A similar bone phenotype has been reported when Cx43 function is disrupted by
overexpressing the mutant oculodentodigital dysplasia (ODDD) Gja1 allele under the
control of the Dermo1 promoter (19). These mouse models of Cx43 deletion exhibit changes
in the geometry of long bones resulting in tubular-like shape, which is also present in
patients with ODDD (21). This can be hardly explained by defective osteoblast
differentiation, raising the possibility that part of the phenotype of mice in which Cx43 was
deleted using the early promoters (Dermo1 and Col1-2.3kb) is due to the contribution of
more mature osteoblasts and in particular of osteocytes.
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In the current study we investigated the consequences of Cx43 deletion in osteocytes in vivo
using mice in which Cx43 was deleted from both mature osteoblasts and osteocytes using
the human osteocalcin (OCN) promoter (22) or exclusively from osteocytes using the dentin
matrix protein 1 (DMP1)-8kb promoter. We found that lack of Cx43 expression exclusively
in osteocytes is sufficient to elicit the long bone phenotype observed in the aforementioned
animal models. Moreover, we showed that bone formation and resorption are associated
with a marked increase in osteocyte apoptosis. These changes in the activity of osteoclasts
and osteoblasts result from an osteocyte cell autonomous decrease in OPG expression and a
reduction in sclerostin-expressing osteocytes as a consequence of the loss of viable cells. In
conclusion, our findings provide support for the intrinsic role of Cx43 in the control of bone




Mice with deletion of Cx43 from osteocytes and osteoblasts (Cx43ΔOb-Ot/-) or exclusively
from osteocytes (Cx43ΔOt) were generated using the Cre/LoxP system (23,24). Cx43ΔOb-Ot/-
mice and Cx43fl/- control littermates were generated by crossing mice homozygous for the
floxed Cx43 gene (Cx43fl/fl mice) (25), generated by K. Willecke, Universitat Bonn, Bonn,
Germany, or Cx43+/- mice (26), generated by J. Rossant, University of Toronto, ON, Canada,
to facilitate the complete deletion of Cx43 in osteocytes and osteoblasts. Cx43fl/- mice were
then crossed with mice expressing Cre recombinase driven by the human osteocalcin
promoter (OCN-Cre mice) (27), generated by T. Clemens, Johns Hopkins University School
of Medicine, Baltimore, MA. Effective deletion of Cx43 from osteoblasts and osteocytes in
these mice was demonstrated earlier by a reduction in Cx43 mRNA of 70%, as determined
by qPCR in cultured calvaria cells, and the lack of Cx43 protein expression demonstrated by
immunostaining in bone sections (22). Female mice at 4.5 months of age (n=6-11 per group)
were administered daily subcutaneous injections of 0.75 mg/kg alendronate or the equivalent
volume of saline for 31 days, as previously published (22).
To delete Cx43 from osteocytes only, we generated Cx43ΔOt mice. In this case, we used
Cx43fl/fl mice, instead of Cx43fl/-, since more recent evidence demonstrated efficient
deletion of Cx43 also using Cx43fl/fl mice (28). Cx43ΔOt mice and Cx43fl/fl control
littermates were generated by crossing Cx43fl/fl mice with DMP1-8kb-Cre mice, which
express Cre recombinase under the control of a 12kb DNA fragment containing 8 kb of the
5′-flanking region, the first exon, the first intron, and 17bp of exon 2 of the murine DMP1
gene (29). DMP1-8kb-Cre mice were produced by microinjection of purified DNA into
pronuclei of C57BL/6 mice at the transgenic mouse core facility of the University of
Arkansas for Medical Sciences. Cx43ΔOt mice and Cx43fl/fl control littermates are
genetically similar, since both Cx43fl/fl and DMP1-8kb-Cre mice were generated in a
C57BL/6 background.
Mice were genotyped by PCR using specific primer sets (25,27,30,31). The presence of the
deleted allele of Cx43 and endogenous DMP1 was evaluated by PCR in genomic DNA
extracted from brain, kidney, heart, skeletal muscle (gastrocnemius), and bone (tibia), as
described elsewhere (5,20). Mice were born at the expected Mendelian frequency, were
fertile, and exhibited normal size and weight. Female mice at 4.5 months of age (n=6-11 per
group) were used for the phenotypic analysis. For the longitudinal BMD studies, female
mice between 1 and 4 month of age (n=9-17 per group) were used. Protocols involving mice
were approved by the Institutional Animal Care and Use Committee of Indiana University
School of Medicine
Bivi et al. Page 3














Mice were injected intraperitoneally with tetracycline HCl or calcein (30 mg/kg, Sigma
Chemical, St. Louis, MO) 7 and 3 days before sacrifice, as previously described (7).
Fluorochrome labels were quantified using Bioquant OSTEO 7.20.10 (Bioquant Image
Analysis Co., Nashville, TN) or OsteoMeasure High Resolution Digital Video System
(OsteoMetrics, Inc., Decatur, GA) (32,33). A value of 0.1 μm/day was used for mineral
apposition rate (MAR) when only single label was present in order to allow calculation of
bone formation rate (BFR/BS) (34). Analyses were performed on longitudinal femoral 5 μm-
thick sections from the midshaft up to 2.5 mm towards the distal end or on 150 μm-thick
cross-sections at the middiaphysis, in order to evaluate the anatomical distribution of the
histological parameters. The terminology and units are those recommended by the
Histomorphometry Nomenclature Committee of the ASBMR (35).
Transmission electron microscopy (TEM)
Femoral midshaft cross-sections were decalcified and post-fixed in 2% paraformaldehyde/
2% glutaraldehyde in 0.1M cacodylate buffer for 1h, followed by 1h-treatment with 1%
osmium tetroxide in 0.1M cacodylate buffer. The bone specimens were then dehydrated,
embedded in Embed 812 resin (Electron Microscopy Sciences, Hatfield, PA), and thin
sectioned using a Diatome diamond knife (Electron Microscopy Sciences, Hatfield, PA) at a
thickness of 70-90 nm. Sections were placed on copper grids, stained with uranyl acetate,
and viewed on a Tecnai G2 12 Bio Twin electron microscope (FEI, Hillsboro, OR) at the
Electron Microscopy Center of the Department of Anatomy and Cell Biology (Indiana
University School of Medicine). Digital images were taken with an Advanced Microscope
Techniques (Danvers, MA) CCD camera.
Bone turnover markers
Plasma osteocalcin (OCN) was measured using enzyme radiometric or linked
immunoadsorbent assays (Biomedical Technologies, Soughton, MA), as published (6,33).
Plasma C-telopeptide fragments of type I collagen (CTX) were measured using an enzyme
linked immunoadsorbent assay (RatLaps, Immunodiagnostic Systems Inc., Fountain Hills,
AZ), as published (33).
Bone mineral density (BMD) and micro-computed tomography (μCT) analysis
BMD of the total body (excluding the head), of the spine (L1-L6), and femur was
determined by dual energy x-ray absorptiometry (DXA) using a PIXImus II densitometer
(G.E. Medical Systems, Lunar Division, Madison, WI), as previously described (5). For μCT
analysis, femora were dissected, cleaned of soft tissue, fixed, and stored in 70% ethanol until
analyzed at 6 μm resolution using a Skyscan 1172 instrument (SkyScan, Kontich,
Belgium) (5).
Calvaria cell isolation
Osteoblastic cells were obtained from calvarial bones of neonatal mice and cultured at an
initial density of 5×104/cm2 for 6 days in the presence of α-MEM supplemented with 10%
fetal bovine serum and 50μg/ml ascorbic acid, as published.(22,36) Half of the medium was
replaced by fresh medium every other day.
Osteocyte isolation and osteocyte-enriched bone preparation
Calvaria cells were isolated from double transgenic mice DMP1-8kb-GFP/DMP1-8kb-Cre.
GFP-expressing cells (osteocyte-enriched) were separated from GFP-negative cells
(osteoblast-enriched) by sorting the cell suspension using a FACSAria flow cytometer (BD
Biosciences, Sparks, MD) at the Indiana University Flow Cytometry Core Facility (5). To
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obtain mRNA from osteocyte-enriched bone preparations, the epiphyses of the femora and
tibiae were cut off, the bone marrow was flushed out using phosphate buffered saline, and
the periosteum was mechanically removed. The obtained diaphyses were then digested 4
times (one hour each) to further remove osteoblastic cells with a mixture of 1.5U/ml
Collagenase P (Roche Applied Science, Indianapolis, IN), 0.05% Trypsin and 1mM EDTA
(Invitrogen, Carlsbad, CA), as published by Kramer et al (4), with modifications.
RNA extraction and quantitative PCR (qPCR)—RNA was purified using Ultraspec
(Biotecx Laboratories, Houston, TX) or SurePrep RNA isolation kit (Fisher scientific,
Pittsburgh, PA). qPCR was performed as described (5), using the house-keeping genes
mitochondrial ribosomal protein S2 (Mrps2) or glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), and the ΔCt method (5). Primers and probes for floxed-Cx43, CRE recombinase
and RANKL were manufactured by Assays-by-Design (Applied Biosystems, Foster City,
CA). The remaining primers were designed using the Assay Design Center (Roche Applied
Science, Indianapolis, IN) or were commercially available (Applied Biosystems, Foster
City, CA).
Western Blot analysis—Protein lysates from MLO-Y4 cells were prepared as previously
reported (15,37). Proteins were separated on 10% SDS-polyacrylamide gels and
electrotransferred to polyvinylidene difluoride membranes. Immunoblottings were
performed using rabbit anti-Cx43 (Sigma, St. Louis, MO) or rabbit anti-ERK1/2 (Santa Cruz
Biotechnology, Santa Cruz. CA), followed by anti-rabbit antibodies conjugated with
horseradish peroxidase (Santa Cruz Biotechnology, Santa Cruz, CA). The intensity of the
bands was quantified using the Fotodyne system (Hartland, WI).
TUNEL, immunohistochemistry and TRAP staining
Longitudinal sections of the femora were used to analyze Cx43ΔOb-Ot mice, and transversal
sections were used for Cx43ΔOt mice with the purpose of spatially map the changes in
osteocytes, osteoblasts and osteoclasts within the cortical bone. Osteocyte apoptosis was
detected by TdT-mediated dUTP nick-end labeling (TUNEL) using a modified version of a
commercial kit (Calbiochem, Gibbstown, NJ) in sections counterstained with 2% methyl
green, as previously described (22). Longitudinal sections were used to determine the
expression of Cx43 using anti-Cx43 antibodies (Sigma Chemical Co., St. Louis, MO) in the
distal femora (22). Consecutive 5 μm-thick sections at the mid-diaphysis were used for
immunohistochemistry with anti-sclerostin antibodies (R&D Systems, Minneapolis,
MN) (6), or anti-RANKL and anti-OPG antibodies (Santa Cruz Biotechnology Inc, Santa
Cruz, CA) with prior antigen retrieval (DeCal Retrieval Solution, BioGenex, San Ramon,
CA) and followed by signal amplification (ABC kit, Vector laboratories, Burlingame, CA).
Non-immune IgG was used as negative control. To visualize osteoclasts on the endocortical
surface, sections were stained for TRAP, as previously described (38). Only TRAP-positive
cells containing >1 nucleus were counted. Bone sections were scored in two anatomical
regions: the outer half (defined as periosteal, Ps) and inner half (defined as endocortical, Ec).
Osteocyte parameters were separately assessed in four regions, two comprising the entire
anterior and posterior regions defined by a 140°-angle from the center of the bone, and two
containing the lateral and medial regions. All the results were reproduced in a separate
cohort of 5 Cx43fl/fl and 5 Cx43ΔOt animals.
Cell viability, apoptosis, and proliferation assays and gene expression in cultured cells
MLO-Y4 cells in which Cx43 expression was silenced using MISSION short hairpin RNA
Lentiviral Particles (Sigma Chemical Co, Saint Louis, MO) were cultured as published (22).
Wild type UMR-106 osteoblastic cells and UMR-106 cells stably transfected with Cx43
were cultured as published (16). MTT assay and Trypan blue uptake were performed as
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previously described (15,39). BrdU incorporation was performed using the BrdU Cell
proliferation ELISA kit (Exalpha Biologicals, Inc., Shirley, MA) following the
manufacturer's instructions. Gene expression was measured by qPCR as indicated above.
Statistical analysis
All values are reported as the mean ± standard deviation (SD) and were analyzed using
SigmaStat (SPSS Science, Chicago, IL). Data were analyzed by two-way ANOVA or t-test
to address specific questions. Specifically, for Fig. 1, two-way ANOVA was performed to
establish the synergy between genotype and alendronate treatment. If a significant main
effect or interaction was found, we examined it closely by performing Pairwise Multiple
Comparisons with Bonferroni correction (40).
RESULTS
Mice lacking Cx43 from osteoblasts and osteocytes (Cx43ΔOb-Ot/- mice) exhibit increased
osteocyte apoptosis in cortical bone and elevated endocortical resorption and periosteal
bone formation
Prompted by evidence that mice lacking Cx43 in osteoblasts and osteocytes (Cx43ΔOb-Ot/-)
exhibited increased osteocyte apoptosis in the cortical shell of the lumbar vertebrae, but not
in the cancellous compartment (22), we investigated whether the prevalence of osteocyte
apoptosis was also high in the diaphysis of the femur, a site entirely composed of cortical
bone. Female Cx43ΔOb-Ot/- mice at 5.5 months of age exhibited a 2.5-fold increase in the
percentage of apoptotic osteocytes, assessed by TUNEL, and a 6-fold increase in the
percentage of empty lacunae, another sign of osteocyte death (41), compared to Cx43fl/-
control littermates (Fig. 1A). Qualitative evaluation by TEM showed features of apoptosis,
including chromatin condensation and nuclear fragmentation, in osteocytes from
Cx43ΔOb-Ot/- mice, whereas osteocyte nuclei in control mice exhibited normal appearance
(Fig. 1B). Increased osteocyte apoptosis in Cx43ΔOb-Ot/- mice was associated with a 2.5-fold
higher number of osteoclasts (NOc/BS) and bone surface covered by osteoclasts (OcS/BS)
on the endocortical surface (Fig. 1C). Bone formation rate (BFR/BS), mineral apposition
rate (MAR), and mineralizing surface (MS/BS) on the periosteal surface were all higher in
Cx43ΔOb-Ot/- mice compared to Cx43fl/- control littermates (Fig. 1D), whereas on the
endocortical surface these indexes of bone formation were not different between groups
(Fig. 1E). Circulating osteocalcin levels were, however, lower in vehicle-treated
Cx43ΔOb-Ot/- mice compared to control littermates (Fig. 1F). This is likely the systemic
expression of a generalized reduction in osteoblast activity due to removal of Cx43 from
osteblasts, as previously shown (20,42).
As a result of the enhanced osteoclast presence on the endocortical surface and increased
bone formation on the periosteal surface, Cx43ΔOb-Ot/- mice exhibited geometric changes
characterized by larger marrow cavity and total tissue area, without changes in cortical
thickness, measured by μCT (Table 1). However, unlike mice in which Cx43 was deleted
using the 2.3kb fragment of the col1a1 promoter (20), Cx43ΔOb-Ot mice did not display low
bone mass or impaired mineralization ((22) and Table 1), indicating that bone mass is
preserved when Cx43 is deleted at a later stage during osteoblast differentiation. The
distribution of cortical bone in a wider cross-section resulted in an increased minimum
moment of inertia (Imin). Consistent with our previous findings in vertebral bone (22),
cancellous bone microarchitecture in the distal femur was not affected by Cx43 deletion
(Table 2).
We next examined whether the elevated periosteal apposition in Cx43ΔOb-Ot/- mice was a
compensatory consequence of the increased endocortical resorption or whether they were
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independent effects of Cx43 deletion. To this end, we evaluated the effect of inhibiting bone
resorption with alendronate on the increased periosteal bone formation observed in
Cx43ΔOb-Ot/- mice. Osteoclasts were not reduced and indeed were increased in
bisphosphonate-treated animals (Fig. 1C), likely due to accumulation of inactive osteoclasts,
as found in humans treated with bisphosphonates (43). However, osteocalcin was markedly
decreased in the circulation of both control and Cx43 deficient mice, indicating an effective
inhibition of bone turnover by the bisphosphonate (Fig. 1F). MS/BS and bone formation rate
on the endocortical surface of control and conditional knock-out mice were also reduced in
alendronate-treated animals (Fig. 1E). This resulted in a reduction in the marrow cavity area
in Cx43ΔOb-Ot/- mice treated with alendronate to reach values comparable to those found in
control mice (Table 1). Alendronate also decreased periosteal BFR/BS in both Cx43
deficient and control mice (Fig. 1D). However, the periosteal surface covered by osteoblasts
and periosteal bone formation rate remained higher in Cx43ΔOb-Ot/- mice treated with
alendronate. Due to the inhibition of endocortical resorption without blocking periosteal
apposition, cortical area and thickness were increased by alendronate administration to both
control and Cx43ΔOb-Ot/- mice (Table 1). These findings are consistent with the regulation
of endocortical resorption and periosteal apposition by Cx43 through independent
mechanisms.
Removal of Cx43 exclusively from osteocytes in Cx43ΔOt mice is sufficient to induce
changes in femoral geometry and increase osteocyte apoptosis
To investigate whether the increased bone formation and resorption and osteocyte apoptosis
in Cx43ΔOb-Ot mice are caused by the removal of Cx43 from osteocytes or whether they are
secondary to the lack of the protein in osteoblasts, we deleted Cx43 exclusively from
osteocytes. Mice expressing Cx43fl/fl were crossed with mice expressing the Cre
recombinase under the control of an 8kb fragment of the DMP1 promoter (DMP1-8kb-Cre
mice). Previous studies demonstrated that several transgenes driven by this fragment of the
DMP1 promoter, including GFP, a constitutively active parathyroid hormone receptor 1, and
human SOST, are expressed in bone and in osteocytes but not in osteoblasts (5,6,29).
Consistent with this earlier evidence, Cre recombinase mRNA was detected only in bone of
Cx43ΔOt mice, but was absent in brain, kidney, heart, and skeletal muscle in 1-month-old
mice (Fig. 2A). Cre was undetectable in all these tissues in Cx43fl/fl mice. Moreover, the
deleted allele of Cx43 was present at high levels in genomic DNA from bone in Cx43ΔOt
mice (Fig. 2B). Low levels of the deleted allele were also present in brain of Cx43ΔOt mice,
consistent with a previous study reporting the expression of the DMP1-8kb-GFP transgene
in a restricted population of brain cells (29). Cx43 mRNA levels were not different between
control and Cx43ΔOt mice in cortical bone preparations likely due to the presence of
osteoblasts, as indicated by the expression of keratocan, a gene more abundant in osteoblasts
than in osteocytes (44) (Fig. 2C). In fact, removal of residual osteoblasts by enzymatic
digestion eliminated keratocan expression and revealed that in this osteocyte-enriched
cortical bone preparation that express SOST, as expected, Cx43 mRNA levels were
decreased by about 85% in Cx43ΔOt mice compared to littermate controls, demonstrating
effective deletion of the gene from osteocytes.
Recent evidence showed that a 10kb fragment of the DMP1 promoter might target the
expression of Cre recombinase not only to osteocytes but also to some mature
osteoblasts (45,46). To determine whether the shorter 8kb fragment of the DMP1 promoter
used in our studies confers Cre expression exclusively to osteocytes and not to osteoblasts,
DMP1-8kb-Cre mice were crossed with DMP1-8kb-GFP mice (29) and neonatal calvaria
cells from DMP1-8kb-Cre; DMP1-8Kb-GFP double transgenic mice were subjected to
fluorescence activated cell sorting (FACS) to separate GFP positive osteocytes from GFP
negative osteoblasts, as previously reported (5). GFP positive osteocytes (Ot) expressed high
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levels of the osteocyte marker SOST while keratocan was low, and GFP negative osteoblasts
(Ob) had undetectable transcripts for SOST, while they expressed higher levels of keratocan
(Fig. 2D), confirming the identity of the cell populations. Cre recombinase was only
detected in GFP positive osteocytes, demonstrating its osteocyte-specific expression.
Moreover, Cx43 protein was reduced selectively in osteocytes, but not in osteoblasts, in
Cx43ΔOt femoral metaphysis, as detected by immunostaining (Fig. 2E).
Cx43ΔOt mice showed higher total tissue, cortical, and marrow cavity areas, without changes
in cortical thickness, resulting in higher minimum moment of inertia (Imin) (Table 3). In
spite of the increased Imim (Tables 1 and 3), bones from Cx43ΔOb-Ot or Cx43ΔOt mice did
not exhibit increased bone strength (data not show). Similar to mice lacking Cx43 from
osteoblasts and osteocytes (22), deletion of Cx43 only from osteocytes did not affect bone
mass. Total, femoral, and spinal BMD of Cx43fl/fl and Cx43ΔOt mice measured by Dexa
were similar at 1, 2, 3 and 4 month of age, except for a slight decrease in total BMD at 2
month of age in the Cx43ΔOt mice (Supplementary Fig. 1A). Bone density measured by
μCT (Table 3) and femoral length (Supplementary Fig. 1B) were also not affected by
Cx43 deletion from osteocytes in 4.5-month-old mice (Table 3). In cancellous bone, BV/
TV, trabecular thickness, number, and separation measured in the femoral metaphysis were
not different between the two groups (Table 4). Only a small, but significant, increase in
circulating osteocalcin and no difference in C-telopeptide were found in Cx43ΔOt mice
compared to controls (Supplementary Fig. 1C). The lack of systemic changes in bone mass
and resorption markers is consistent with an effect of Cx43 deletion localized to specific
bone compartments. On the other hand, circulating osteocalcin levels were slightly
increased, likely as the result of the combination of localized increase in both bone
formation and resorption.
Expression of Cx43 in osteocytes is required to maintain osteocyte viability and to control
the RANKL/OPG ratio in a cell autonomous manner
We then investigated whether deletion of Cx43 exclusively from osteocytes lead to similar
changes in osteocyte viability than removal of the protein from both osteoblasts and
osteocytes. Cx43ΔOt mice exhibited a marked increase in the prevalence of osteocyte
apoptosis and empty lacunae (Fig. 3A and Supplementary Fig. 2), suggesting a direct
requirement of Cx43 in osteocytes to maintain cell viability. Osteocyte apoptosis has been
associated with osteoclast recruitment and localized removal of bone (7-9,47); and targeted
death of osteocytes is sufficient to initiate bone resorption (10). Based on this evidence, we
next mapped apoptotic osteocytes, empty lacunae, and osteoclasts in different regions of
femoral midshaft cross-sections to explore the potential co-localization of these phenomena.
Towards this end, the cortex was divided in two equivalent regions: one close to the bone
marrow (endocortical, Ec) and the other close to the periosteum (periosteal, Ps); and also in
four anatomical regions: anterior, lateral, posterior, and medial (Fig. 3B), following earlier
approaches (7,9). The accumulation of apoptotic osteocytes was observed in both the
periosteal and endocortical halves of the cortex in Cx43ΔOt mice compared to controls (Fig.
3C). In addition, empty lacunae were uniformly abundant throughout the four anatomical
regions of the cortex. In contrast, apoptotic osteocytes were higher in the posterior region of
Cx43ΔOt mice compared to controls. The prevalence of apoptotic osteocytes among the four
regions for either phenotype was not different. Osteoclasts were found only on the
endocortical surface and were also more abundant in the posterior region, as well as in the
medial region of the cortex (Fig. 3D).
Consistent with the lack of systemic changes in resorption, mRNA for RANKL and OPG in
whole bones are not different in Cx43ΔOt mice compared to controls (not shown). This
finding prompted us to investigate potential changes in local gene expression. RANKL and
OPG were readily detected by immunostaining in osteocytes in bone sections from Cx43ΔOt
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mice as well as control littermates (Fig. 3E and F and Supplementary Fig. 4 and 5).
Moreover, whereas the percentage of osteocytes expressing RANKL was not affected by
Cx43 deletion (Fig. 3E), the prevalence of OPG-expressing osteocytes was markedly and
uniformly reduced in all cortical regions of Cx43ΔOt mice (Fig. 3F). Similar results were
obtained when the prevalence of OPG-expressing osteocytes was calculated by dividing the
number of positive cells by the number of total lacunae (Fig. 3F) or of occupied lacunae
only (Supplementary Fig. 2B), indicating that decreased OPG was the result of changes in
the expression of the gene and not secondary to the loss of osteocytes. Moreover, the
osteocytes showing decreased OPG expression do not appear to correlate with those
undergoing apoptosis. Thus, in Cx43ΔOt mice, the prevalence of OPG-expressing osteocytes
was decreased also in regions in which TUNEL staining of adjacent sections did not show
accumulation of apoptotic osteocytes.
To determine whether deletion of Cx43 results in a direct effect on osteocyte viability, we
used MLO-Y4 osteocytic cells in which the expression of the protein was silenced using
shRNA. Effective deletion of Cx43 was demonstrated at the mRNA and protein level (Fig.
4B). Apoptosis was assessed using Trypan blue uptake, a reliable method that correlates
with DNA fragmentation, as detected by TUNEL, a recognized hallmark of apoptosis (48).
Consistent with the increased osteocyte apoptosis found in Cx43ΔOt mice, cultures of MLO-
Y4 osteocytic cells in which Cx43 expression was silenced displayed lower number of
viable cells due to higher basal levels of apoptosis at 1 to 3 days in culture, compared to
MLO-Y4 cells silenced with scrambled shRNA (Fig. 4A). On the other hand, proliferation
of Cx43 deficient cells, as assessed by BrdU incorporation, did not change throughout the
culture period; whereas it declined for Cx43 expressing cells as cultures reached confluence.
In addition, RANKL expression was higher and OPG expression was lower in MLO-Y4
cells lacking Cx43 compared to MLO-Y4 cells expressing Cx43, resulting in approximately
a 4-fold increase in the RANKL/OPG ratio (Fig. 4B). Similar results were obtained with
primary cultures of calvaria cells derived from Cx43ΔOt mice (Fig. 4C). Taken together,
these results indicate that Cx43 is required in a cell autonomous manner to maintain
osteocyte viability and to regulate the RANKL/OPG ratio.
Increased periosteal bone apposition and endocortical bone formation in Cx43ΔOt mice is
localized in areas of low sclerostin levels due to loss of viable osteocytes
The larger femora cross-section displayed by Cx43ΔOt mice was associated with increased
periosteal bone apposition, as demonstrated by increased BFR/BS, MAR and MS/BS (Fig.
5A). Similar to our findings with osteoclast surface, periosteal bone formation was
selectively activated in defined portions of the cortex. Thus, BFR/BS was increased in the
posterior and medial periosteal surfaces in Cx43ΔOt femora, resulting from higher MAR.
Consistent with the role of sclerostin as a paracrine inhibitor of bone formation (2,49), the
percentage of osteocytes expressing sclerostin was significantly reduced in the periosteal
half of the femoral cortex in Cx43ΔOt mice. Moreover, sclerostin-expressing osteocytes were
reduced in the posterior and medial regions of the periosteal half, areas in which bone
formation was increased, as well as in the anterior region (Fig. 5A and Supplementary Fig.
6). Bone formation was also enhanced on the endocortical surface and it was localized to the
anterior portion of the cortex, where the prevalence of sclerostin-positive osteocytes per total
lacunae was decreased (Fig. 5B). In contrast to OPG-expressing osteocytes, the decrease in
the prevalence of sclerostin-expressing osteocytes was eliminated when the number of
positive cells was divided by the number of occupied lacunae (Supplementary Fig. 2C),
suggesting that deletion of Cx43 does not reduce SOST expression in individual osteocytes.
We confirmed that changes in Cx43 levels do not affect SOST expression in vitro by
comparing the expression of the gene in UMR-106 cells, which exhibit low Cx43
expression, and UMR-43 cells, a cell line derived from UMR-106 cells that overexpresses
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Cx43 (16). In contrast to MLO-Y4 cells, which do not express SOST transcripts, UMR-106
cells express high levels of SOST and low levels of Cx43 that can be increased by stable
transfection (16,50,51). Even when Cx43 expression was significantly lower in UMR-106
wild type cells compared to UMR-43 cells, both cell types expressed similar SOST levels
(Fig. 4D). Thus, this in vivo and in vitro evidence strongly suggest that whereas decreased
OPG expression is due to an intrinsic reduction in gene expression, decreased sclerostin
levels result from loss of viable osteocytes in Cx43ΔOt mice.
DISCUSSION
The findings of the present study demonstrate conclusively that Cx43 is required in a cell
autonomous fashion to preserve the viability of osteocytes and to control in osteocytes the
levels of proteins that regulate the generation and activity of osteoclasts and osteoblasts.
Cx43 deficiency causes an intrinsic reduction in OPG expression and loss of viable
osteocytes, with the consequent decrease in local levels of the bone formation inhibitor
sclerostin. Our results indicate that there is a potential cause-effect relationship between
these molecular events and the exacerbated endocortical resorption and periosteal bone
formation in selected areas of the cortex, which alter bone geometry (Fig. 6). Bone
formation and resorption triggered by Cx43 removal occur on separate, non-overlapping
locations within cortical bone, suggesting that the two events are not coupled during bone
remodeling, and that instead the absence of Cx43 enhances formation and resorption due to
modeling. Remarkably, the bone surfaces that show increased activity in the Cx43
conditional knock-out mice are the same ones that are subjected to modeling during
growth (52), suggesting the potential involvement of osteocytes and Cx43 in this
physiological process. In addition, Cx43ΔOb-Ot/- and Cx43ΔOt mice display features that
resemble bones from aging rodents and humans, including accumulation of apoptotic
osteocytes and empty lacunae and periosteal expansion of the long bones (41,53). Because
Cx43 is a Wnt target gene (54) and Wnt signaling decreases with age in bone (55), our
findings raise the possibility that reduction in Cx43 expression due to decreased Wnt
signaling could mediate at least some of the changes induced by aging in the skeleton.
Previous reports have shown that deletion of Cx43 from osteochondroprogenitors or from
early osteoblast progenitors, or the disruption of its function by expressing a
oculodentodigital dysplasia-like Cx43 mutant, result in reduced bone mass due to deficient
osteoblast differentiation and function (19,20,56-58). However, deletion of Cx43 from mature
osteoblasts and osteocytes (22) or from osteocytes only (this report), does not cause a
decrease in bone mass, indicating that Cx43 is specifically required for osteoblast maturation
during early stages of differentiation and its removal from cells at a more mature
osteoblastic stage does not affect bone mass. On the other hand, the widening of the long
bones, a phenotypic feature present in the mouse models of early Cx43 deletion, was
reproduced in Cx43ΔOt mice. This indicates that the removal of Cx43 from osteocytes is
sufficient to elicit the changes in the geometry typical of Cx43 deletion and further supports
the notion that Cx43 expression specifically in osteocytes is required to regulate bone
modeling in cortical bone.
The decrease in osteocalcin levels in Cx43ΔOb-Ot/- mice is likely the systemic expression of
a generalized reduction in osteoblast activity due to Cx43 removal from osteoblasts. Indeed,
it was previously shown that Cx43-deficient osteoblasts express low levels of
osteocalcin (20,42). On the other hand, deletion of Cx43 from osteoblasts and osteocytes
enhances the bone-forming activity of periosteal cells, as shown by us and others (19),
suggesting that the activity of cells on the periosteal and endocortical surfaces is regulated
by different mechanism. Consistent with this, deletion of Cx43 only from osteocytes in
Cx43ΔOt mice results in a significantly higher circulating osteocalcin level, likely resulting
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from the enhanced osteoblastic activity in both endocortical and periosteal surfaces and lack
of impairment of osteoblast function in other surfaces. Moreover, our studies raise the
possibility that osteocytes and osteocyte apoptosis are novel players in the establishment of
geometrical phenotype caused by ODDD-related mutations.
Our study is the first one to demonstrate that lack of Cx43 in osteocytes leads to their
apoptosis. These findings are consistent with earlier studies of ours in which Cx43 was
shown to act as a transducer of cell survival signals generated by bisphosphonates in
osteoblasts and osteocytes (16,22). Our current study raises the possibility that physiological
pro-survival signals for osteocytes are also transduced by Cx43, although the identity of the
endogenous stimuli that protect osteocytes from apoptosis is not known. Similar to lack of
Cx43, weightlessness induced by unloading in vivo in rodents or in vitro in human explants,
increases the prevalence of osteocyte apoptosis (7,59-61). Conversely, mechanical stimulation
prevents apoptosis of osteocytic cells (62,63), and induces opening of Cx43
hemichannels (64), which in turn is required for the release of prostaglandins and
preservation of cell survival (65). Taken together this evidence suggests that mechanical
forces might require Cx43 to maintain osteocyte viability. Local factors present in the bone
microenvironment might also activate Cx43-dependent signaling. A potential candidate is
IGF-I, which prevents apoptosis of osteoblastic cells in vitro and increases the percentage of
occupied osteocyte lacunae in vivo (66,67), by a mechanism that might require Cx43, as
shown for cardiomyocyte progenitor cells (68). Similar to our findings demonstrating that
lack of Cx43 leads to apoptosis of osteocytes but not of osteoblasts, mechanical stimulation
and IGF-I appear to differentially affect survival of these two cell types. Thus, osteoblasts
and osteocytes exhibit different sensitivity to mechanical forces in vitro (69,70); and, whereas
osteocytic cells open Cx43 hemichannels in response to mechanical stimulation, osteoblastic
cells do not (71). In addition, mice overexpressing IGF-I in osteoblastic cells do not exhibit
changes in osteoblast viability, while they appear to display prolonged osteocyte
survival (67). Future studies will be required to identify physiologic cues that require Cx43 to
maintain osteocyte viability.
The intracellular survival events activated downstream of Cx43 under physiological
conditions also remain unknown. We have shown that the Cx43-dependent survival effect of
bisphosphonates on osteocytes is mediated by activation of Src and the survival kinases
ERKs (16). In addition, osteoblastic cells with deficient Cx43 function exhibit reduced ERK
activation in response to growth factors (72). Moreover, mechanical stimulation, systemic
hormones, as well as local factors such as Wnts and IGF-I, all known ERK-activating
stimuli, prevent apoptosis of osteoblastic cells (73). Whether alterations in the ERK pathway
are responsible for increased osteocyte apoptosis in the absence of Cx43 will require future
investigations.
Our studies show apoptotic osteocytes only in cortical bone but not in cancellous bone of
mice with conditional deletion of Cx43. In addition, Cx43 protein expression appears to be
higher in the cortical envelope, compared to the cancellous compartment in control mice
(not shown), consistent with recent evidence suggesting higher expression of Cx43 in
osteocytes in cortical versus cancellous bone (19). This differential expression raises the
possibility that higher levels of Cx43 are required to maintain viability of osteocytes in
cortical bone, compared to cancellous bone. In addition, intrinsic differences in threshold
sensitivity to environmental cues between cells in these two bone envelopes could explain
this phenomenon. Alternatively, the failure to detect increases in the prevalence of osteocyte
apoptosis in cancellous bone could be explained by the higher rate of remodeling in this
compartment compared to cortical bone, which would not allow accumulation of apoptotic
osteocytes. Consistent with this hypothesis, we have shown in a previous study that
inhibition of resorption by alendronate administration to Cx43ΔOb-Ot/- mice led to a
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significant increase in the prevalence of osteocyte apoptosis in vertebral cancellous bone,
reaching values close to those observed in cortical bone (22). Thus, apoptotic osteocytes
might accumulate as the animals age as a result of the decreased rate of bone
remodeling (53), suggesting that a cancellous bone phenotype could become evident in older
mice.
The association between osteocyte apoptosis and increased osteoclasts on adjacent
endocortical surfaces in Cx43ΔOt mice is consistent with previous evidence suggesting that
dying osteocytes recruit osteoclasts to the vicinity (11). Blockade of osteocyte apoptosis with
caspase inhibitors prevented the expected increase in bone resorption induced by fatigue
loading or ovariectomy (8,9). However, the mechanism of this osteocyte-induced osteoclast
recruitment is not known. In an attempt to identify molecules produced by osteocytes that
could induce local resorption, we mapped the number and distribution of osteocytes
expressing RANKL and OPG, molecules shown to be expressed by osteocytes (3,4). To do
this, we performed immunohistochemistry staining of bone sections using specific
antibodies directed against RANKL and OPG. Although not quantitative, this approach is
ideal to show the expression of RANKL and OPG in osteocytes and the spatial distribution
of the two proteins in relation to osteoclasts. Expression of RANKL and OPG mRNA and
protein was readily detected in bone lysates or sections, respectively, although no
differences were detected in bone lysates from Cx43ΔOt mice compared to wild type
littermates (not shown). Moreover, the percent of RANKL positive osteocytes was similar
between the two mouse strains. On the other hand, the number of osteocytes expressing
OPG was markedly reduced in conditional knock-out mice. This is similar to the recent
findings in mice lacking Cx43 in osteochondroprogenitors, which also exhibit an increased
RANKL/OPG ratio due to reduced levels of OPG (19), strongly suggesting that removal of
Cx43 from osteocytes is responsible for the changes observed in the later mouse model.
However, in our Cx43ΔOt model osteocytes expressing low levels of OPG were equally
distributed throughout the cortex, suggesting that an increase in RANKL/OPG ratio is not
sufficient to increase resorption and that additional signals are required to target osteoclasts
to particular areas of the bone. Empty osteocyte lacunae were also evenly distributed
throughout the cortical bone, arguing against the possibility that osteoclast recruitment
results from loss of osteoclast-restraining signals released by living osteocytes, as previously
suggested (74). In contrast, we found that apoptotic osteocytes were located nearby
osteoclasts, supporting the notion that during the process of undergoing apoptosis,
osteocytes actively emit signals that promote recruitment and differentiation of osteoclast
progenitors (75). This is consistent with previous reports showing that dying osteocytes
release apoptotic bodies, which induce osteoclast differentiation (47). Indeed, we observed
TUNEL positivity not only in osteocytic cell bodies but also within canaliculi, suggesting
that fragmented DNA and potentially other components of dying cells escape to the
canalicular network. These chemotactic signals could be, in turn, transported through the
canaliculi to regions adjacent to the ones in which they were produced. This could explain
our finding that osteoclast number is also higher in the medial region, in the absence of
increased osteocyte apoptosis in the same area. Taken together with previous evidence, our
findings suggest that, reduced OPG expression may be a permissive event, and that signaling
molecules derived from dying osteocytes, may act as chemo-attractants for osteoclast
precursors to trigger bone resorption at specific locations.
Reduced percentage of OPG-expressing osteocytes was found independently of whether
OPG-expressing cells were divided by total number of lacunae or by occupied lacunae only,
thus indicating that reduction in OPG is not a consequence of loss of viable osteocytes. This,
together with the findings that OPG mRNA expression is decreased in cultured MLO-Y4
cells lacking Cx43, confirms a cell autonomous regulation of OPG by Cx43 and raises the
possibility that Cx43 directly controls the transcription of OPG. Expression of both Cx43
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and OPG is increased by Wnt signaling (4,54). Our findings showing that mice lacking Cx43
in osteocytes exhibit low OPG expression raise the possibility that Wnt signaling
upregulates OPG by a mechanism that involves Cx43. Besides containing consensus Lef1/
Tcf binding sequences through which the Wnt pathway directly increases gene
expression (76), the OPG promoter also displays binding sites for Sp1 and p53 (77,78),
transcription factors known to be regulated by Cx43 (18,79). Thus, it is possible that these
Cx43-dependent transcription factors interact with Wnt/βcatenin to enhance transcriptional
activation of the OPG gene, similar to what it was proposed for BMPs (76). On the other
hand, Cx43 does not appear to directly promote the transcription of SOST/sclerostin, since
overexpression of Cx43 in UMR-106 cells does not affect mRNA levels for SOST. In
contrast to OPG, the percentage of RANKL positive osteocytes is not different in Cx43ΔOt
mice. However, it is possible that each osteocyte expresses more RANKL, which cannot be
quantified by immunohistochemistry. Indeed, MLO-Y4 cells lacking Cx43 do express more
RANKL. Thus, we cannot exclude the possibility that increased RANKL expression in
selected osteocyte populations contributes to increased local RANKL/OPG ratio and
resorption in vivo.
We conclude that Cx43 is differentially required for maintaining osteocyte viability in
cortical but not cancellous bone in a cell autonomous manner. Deletion of Cx43 from
osteocytes also alters gene expression and bone formation and resorption, which result in
changes in bone geometry. Whether these effects of Cx43 result from the ability of the
protein to mediate osteocyte communication with other cells or with the extracellular milieu
or are due to its interaction with signaling molecules resulting in modulation of intracellular
pathways will require further investigation.
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Figure 1. Deletion of Cx43 from osteocytes and osteoblasts results in increased cortical osteocyte
apoptosis, endocortical osteoclastic surface and periosteal apposition
(A) Apoptotic (TUNEL positive) osteocytes were scored in the cortical bone of femora, 2.5
mm from the midshaft towards the growth plate. Representative images show examples of
living (black arrows) and apoptotic (red arrows) osteocytes. ALN: alendronate. nd: non-
detectable. (B) Representative TEM images of osteocytes in femoral midshaft. (C)
Osteoclast number and surface were determined on the endocortical surface of the femoral
midshaft. Representative images of bone sections stained for TRAP. Arrows point to TRAP
positive osteoclasts. (D and E) Dynamic histomorphometric parameters were measured on
the periosteal (D) and endocortical (E) surfaces of the femoral midshaft. ALN: alendronate.
(F) Circulating levels of osteocalcin (OCN) measured in plasma. Bars are mean ± SD. *
indicates significant differences versus vehicle-treated Cx43fl/- mice and # indicates
significant differences versus vehicle-treated Cx43ΔOb-Ot/- mice at p<0.05, n = 6-9.
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Figure 2. Effective removal of Cx43 from osteocytes but not from osteoblasts in DMP1-8Kb-
Cre;Cx43fl/fl (Cx43ΔOt) mice
(A) Cre mRNA expression in brain, kidney, heart, skeletal muscle and tibia isolated from
Cx43fl/fl and Cx43ΔOt mice. (B) Genomic DNA was purified from the indicated tissues and
PCR reactions for the deleted allele of Cx43 (Cx43del) and for endogenous DMP1 used as
loading control. (C) mRNA expression of keratocan, SOST, and Cx43 was determined in
cortical bone preparations before (left panels), and after (right panels) enzymatic digestion
with collagenase in order to remove remaining osteoblasts to obtain osteocyte-enriched bone
preparations. Bars are mean ± SD of five determinations (3-5 mice/preparation). * indicates
significant differences versus Cx43fl/fl mice at p<0.05. (D) Messenger RNA expression in
primary osteocytes and osteoblasts isolated from DMP1-8kb-GFP mice expressing Cre
recombinase under the control of the 8kb fragment of the DMP1 promoter. OT: osteocytic
cells; OB: osteoblastic cells. nd: non-detectable. Bars are mean ± SD of triplicate
determinations. (E) Cx43 (brown) expression in femoral cortical bone of Cx43fl/fl and
Cx43ΔOt mice stained with an anti-Cx43 polyclonal antibody or non-immune (n.i.) IgG, and
counterstained with 0.2% methyl green to reveal cell nuclei (green). Red arrows point to
osteocytes and black arrows point to osteoblasts. Representative sections from 3 different
animals per genotype are shown. Bar indicates 20 μm.
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Figure 3. Removal of Cx43 in Cx43ΔOt mice causes increased osteocyte apoptosis localized to the
posterior portion of the femoral cortex, accompanied by targeted osteoclast recruitment
(A) Apoptotic cells were visualized by TUNEL staining (brown) in the total cortical area in
sections counterstained with methyl green (green) to detect viable cells. Percentages were
calculated over the sum of viable osteocytes, apoptotic osteocytes and empty lacunae.
Representative images of the posterior side in specimens stained for TUNEL are shown.
Higher magnification image of TUNEL positive apoptotic osteocytes showing abundant
TUNEL signal within the canalicular system (red arrow), indicating the presence of
fragmented DNA. Bars indicate 20 μm. (B) Schematic indicates the areas in which the
cortical bone was divided to measure the parameters showed in this figure. Measurements
were made in two equally separated halves of the cortex: periosteal region (Ps) and
endocortical region (Ec). Cells were also evaluated around the longitudinal axis in four
different portions: anterior (A), lateral (L), posterior (P), and medial (M). (C) Prevalence of
osteocyte apoptosis and empty lacunae in the two halves and in the four anatomical regions
of the cortex. Bars are mean ± SD. * indicates significant differences versus Cx43fl/fl mice at
p<0.05, n=3-5. (D) Osteoclast number on the endocortex (Ec) was determined in sections
stained for TRAP and counterstained with Toluidine blue. Representative images of the
posterior side stained for TRAP (arrow) are shown (400X). (E and F) The prevalence of
RANKL-expressing (E) and OPG-expressing (F) osteocytes was quantified in sections
stained with specific antibodies. Bars are mean ± SD. * indicates significant differences at
p<0.05 versus Cx43fl/fl mice, n=3-5. Representative images of femoral cross-sections
stained with antibodies directed against RANKL (E) and OPG (F) in Cx43fl/fl mice. Bar
indicates 20 μm.
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Figure 4. Expression of Cx43 in osteocytes is required in a cell autonomous manner to maintain
osteocyte viability and a low RANKL/OPG ratio in vitro
(A) Cell number, viability, and proliferation were evaluated by MTT, Trypan blue uptake,
and BrdU, respectively 1, 2 and 3 days after seeding in MLO-Y4 cells silenced with
scrambled or Cx43 shRNA. Each point corresponds to the mean ± SD of 6-12 replicas. *
indicates significant differences versus scramble shRNA-infected cells for each time point at
p<0.05. (B) Cx43 protein levels were quantified by Western blotting, corrected by ERK1/2
levels. A representative Western blot image is shown. mRNA levels for Cx43, RANKL and
OPG relative to the housekeeping gene Mrps2 were determined by qPCR in MLO-Y4
expressing or not Cx43. Bars are mean ± SD of triplicate determinations. * indicates
significant differences at p<0.05 versus scramble shRNA-infected cells. (C) mRNA levels
for Cx43, RANKL and OPG relative to the housekeeping gene GAPDH were determined by
qPCR in calvaria cells isolated from control Cx43fl/fl and Cx43ΔOt mice. Bars are mean ±
SD of quadruplicate determinations. * indicates significant differences at p<0.05 versus
control. (D) mRNA levels for Cx43 and SOST relative to the housekeeping gene β-actin
were determined by qPCR in Cx43-transfected (UMR+43) and wild type UMR-106 cells.
Bars are mean ± SD of triplicate determinations. * indicates significant differences at p<0.05
versus wild type cells.
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Figure 5. Increased bone apposition in Cx43ΔOt mice coincides with surfaces adjacent to areas
where sclerostin expression is low
(A) Dynamic histomorphometric parameters were measured on the periosteal surface of the
femoral midshaft. Bars are mean ± SD. * indicates significant differences at p<0.05 versus
Cx43fl/fl mice, n=7-8. Representative images of calcein labels are shown. Left, entire cross-
section at low magnification (50X), bar indicates 500 μm; right, high magnification showing
the detail of the double labeling on the posterior region. Arrows point to the periosteal
surface. Dynamic histomorphometric parameters in the anterior (A), lateral (L), posterior
(P), and medial (M) regions around the femoral midshaft, on the periosteal surface. The
prevalence of sclerostin (+) osteocytes was determined in the periosteal (Ps) half as a whole
(total) and divided in the four anatomical regions, stained with anti-sclerostin antibodies and
counterstained with methyl green. Bars are mean ± SD. * indicates significant differences at
p<0.05 versus Cx43fl/fl mice, n=3-8. (B) Dymamic histomorphometric parameters were
measured on the endocortical surface as a whole and divided in the four anatomical regions.
Sclerostin (+) osteocytes were quantified in the endocortical half (Ec) of the bone as a whole
(total) and divided in the four anatomical regions. Arrows point to the endocortical surface.
Bars are mean ± SD. * indicates significant differences at p<0.05 versus Cx43fl/fl mice,
n=3-8.
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Figure 6. Cx43 deficiency increases osteocyte apoptosis and modulates the levels of osteocytic
genes that affect osteoclast and osteoblast function resulting in altered bone geometry
Deletion of Cx43 increases apoptosis and reduces OPG gene expression in osteocytes,
inducing osteoclast recruitment and resorption in the posterior endocortical area.
Accumulation of empty lacunae causes a reduction in sclerostin levels with consequent
increase in bone formation in the anterior endocortical surface and in the posterior periosteal
surface. This results in magnification of the physiological modeling drift (represented by the
arrow) by which long bones adapt their shape to mechanical needs.
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Table 1
Deletion of Cx43 from osteoblasts and osteocytes results in increased tissue, cortical, and marrow cavity area
in the femoral midshaft (μCT analysis)
Cx43fl/- vehicle Cx43ΔOb-Ot/- vehicle Cx43fl/- alendronate Cx43ΔOb-Ot/- alendronate
Total tissue area (mm2) 2.63 ± 0.32 3.32 ± 0.15* 2.56 ± 0.25 3.23 ± 0.17*
Marrow cavity area (mm2) 1.53 ± 0.31 2.10 ± 0.16* 1.26 ± 0.18* 1.63 ± 0.12#
Cortical area (mm2) 1.10 ± 0.09 1.22 ± 0.13* 1.30 ± 0.11* 1.60 ± 0.23*#
Cortical thickness (mm) 0.22 ± 0.02 0.21 ± 0.02 0.25 ± 0.02* 0.28 ± 0.03*#
Imin (mm4) 0.31 ± 0.12 0.43 ± 0.10* 0.27 ± 0.06 0.41 ± 0.07*
Bone density (pixels) 227.87 ± 6.86 223.45 ± 5.63 227.30 ± 5.28 219.71 ± 4.60*
Values are mean ± SD.
*
indicates significant differences versus vehicle-treated Cx43fl/- mice
#
indicates significant differences versus vehicle-treated Cx43ΔOb-Ot/-mice at p<0.05, n = 6-10













Bivi et al. Page 26
Table 2
Deletion of Cx43 from osteoblasts and osteocytes does not affect cancellous bone micro-architecture in the
distal femur (μCT analysis)
Cx43fl/- Cx43ΔOb-Ot/-
BV/TV (%) 14.25 ± 5.28 15.72 ± 8.18
Trabecular separation (mm) 0.06 ± 0.01 0.07 ± 0.01
Trabecular number (N/mm) 2.22 ± 0.78 2.22 ± 1.18
Trabecular thickness (mm) 0.22 ± 0.02 0.21 ± 0.02
Values are mean ± SD, n = 6-10.
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Table 3
Deletion of Cx43 from osteocytes is sufficient to induced increased tissue, cortical, and marrow cavity area of
femoral midshaft (μCT analysis)
Cx43fl/fl Cx43ΔOt
Total area (mm2) 2.06 ± 0.25 2.48 ± 0.12*
Marrow cavity area (mm2) 1.28 ± 0.19 1.62 ± 0.10*
Cortical area (mm2) 0.77 ± 0.08 0.86 ± 0.05*
Cortical thickness (mm) 0.15 ± 0.00 0.15 ± 0.00
Imin (mm4) 0.20 ± 0.05 0.30 ± 0.04*
Bone density (pixels) 213.05 ± 8.42 213.34 ± 5.75
Values are mean ± SD.
*
indicates significant differences versus Cx43fl/fl mice at p<0.05, n = 9-7.
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Table 4
Deletion of Cx43 from osteocytes does not affect cancellous bone micro-architecture in the distal femur (μCT
analysis)
Cx43fl/fl Cx43ΔOt
BV/TV (%) 9.91 ± 4.01 9.66 ± 3.57
Trabecular thickness (mm) 0.05 ± 0.01 0.05 ± 0.00
Trabecular number (N/mm) 1.94 ± 0.65 2.05 ± 0.64
Trabecular separation (mm) 0.22 ± 0.02 0.22 ± 0.03
Values are mean ± SD, n = 8-7.
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